期刊文献+

甲羟孕酮对人卵巢癌顺铂耐药细胞株SKOV3/DDP耐药的逆转作用 被引量:2

The reversible effect of medroxyprogesterone acetate on drug resistance of human ovarian carcinoma cell line SKOV3/DDP to cisplatin
原文传递
导出
摘要 目的:应用甲羟孕酮(Medroxyprogesterone Acetate,MPA)体外逆转人卵巢癌顺铂耐药细胞株SKOV3/DDP的耐顺铂(cisplatin,DDP)效应,并对其作用机制进行初步探讨。方法:采用四甲基偶氮唑蓝(MTT)法检测MPA对SKOV3/DDP的细胞毒作用,确定MPA对此细胞株的非细胞毒性剂量作为逆转剂量,同法测定非细胞毒性剂量MPA联合DDP作用后SKOV3/DDP对顺铂耐药性的变化,采用流式细胞技术(FCM)检测细胞周期及凋亡情况。结果:单用MPA浓度大于7.50 g/L时对SKOV3/DDP细胞有不同程度的抑制作用,且呈剂量依赖性。MPA浓度小于15.85 g/L时,其对细胞生长无明显抑制作用(细胞存活率均>90%),因此选用15.00 g/L作为逆转剂量。DDP联合15.00 g/L的MPA作用24、48、72 h后,顺铂的IC50分别下降至(57.72±0.48)g/L、(13.39±0.21)g/L、(7.93±0.18)g/L,逆转倍数分别为1.22,1.90,2.44倍。DDP与MPA联合作用于SKOV3/DDP细胞,使其细胞周期阻滞于G0/G1期,S期细胞比例下降,并可以增加耐药细胞的凋亡率。结论:MPA可以逆转DDP引发的卵巢癌耐药,其可能的逆转耐药机制为促进细胞的凋亡,阻滞细胞周期进程。 Objective:To reverse the drug resistance of human ovarian carcinoma cell line SKOV3/DDP to cisplatin by medroxyprogesterone acetate(MPA) in vitro,and explore the mechanism preliminarily. Methods:MTT method was used to detect the cytotoxicity of MPA to SKOV3/DDP cells,the non-cytotoxic dose was selected as reversible dose,the change of drug resistance of SKOV3/DDP to cisplatin was detected after treated with MPA of non-cytotoxic dose combined with cisplatin,flow cytometry was used to detect cell cycle and apoptosis. Results:When the concentration of MPA was higher than 7.50 g/L,MPA inhibited SKOV3/DDP cells of varying degrees,showing a dose-dependent manner.When the concentration of MPA was lower than 15.85g/L,MPA had no apparent inhibiting effect on cell growth(cell survival rate〉90%),thus,15.00 g/L was selected as reversible dose.After treating SKOV3/DDP cells by cisplatin combined with MPA(15.00 g/L) for 24,48 and 72 hours,the IC50 values of cisplatin decreased to(57.72±0.48) g/L,(13.39±0.21) g/L and(7.93±0.18) g/L,respectively;the reversal multiples were 1.22,1.90 and 2.44,respectively.The cell cycle of SKOV3/DDP cells was arrested at G0/G1 phase after treated with cisplatin combined with MPA,the proportion of SKOV3/DDP cells at S phase decreased,and the apoptosis rate increased. Conclusion:MPA can reverse the drug resistance of ovarian carcinoma to cisplatin,the possible mechanism is MPA can promote cell apoptosis and arrest the course of cell cycle
作者 张翔 韩萍
出处 《中国妇幼保健》 CAS 北大核心 2011年第11期1699-1701,共3页 Maternal and Child Health Care of China
关键词 卵巢癌 甲羟孕酮 耐药逆转 凋亡 Ovarian carcinoma Medroxyprogesterone acetate Drug resistance reversal Apoptosis
  • 相关文献

参考文献6

二级参考文献35

  • 1谢守珍,王晶,李德忠,王艳.醋酸甲羟孕酮对卵巢癌裸鼠移植瘤的抗血管生成作用[J].第一军医大学学报,2004,24(7):821-823. 被引量:5
  • 2汤群锋,沈钧康,冯一中,柴玉海,钱铭辉.胃癌动态增强MRI表现与肿瘤血管形成关系的研究[J].中华放射学杂志,2004,38(10):1075-1080. 被引量:22
  • 3谢守珍,王晶,宋成文,陈枝岚.甲羟孕酮对孕激素受体阳性/阴性癌组织诱导血管形成的抑制作用[J].医药导报,2005,24(5):390-392. 被引量:3
  • 4王海勇,王林.抗血管生成疗法有可能成为癌症化疗增敏新策略[J].国外医学(药学分册),2006,33(6):464-465. 被引量:2
  • 5Ferlini C,Raspaglio G,Mozzetti S,et al.Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance[J].Mol Pharmacol,2003,64 (1):51-58.
  • 6Kim R,Emi M,Tanabe K,et al.Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy[J].Tutorial Cancer,2004,101(11):2491-2502.
  • 7Yang X,Fraser M,Moll UM,et al.Akt-mediated cisplatin resistance in ovarian cancer:modulation of p53 action on caspase-dependent mitochondrial death pathway[J].Cancer Res,2006,66(6):3126-3136.
  • 8Pennati M,Campbell AJ,Curto M,et al.Potentiation of paclitaxelinduced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140:a possible role of surviving down-regulation[J].Mol Cancer Ther,2005,4(9):1328-1337.
  • 9Zhou J,O'brate A,Zelnak A,et al.Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol[J].Cancer Res,2004,64(23):8708-8714.
  • 10Duan Z,Brakora KA,Seiden MV.Inhibition of ABCB1 (MDR1) and ABCB4(MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells[J].Mol Cancer Ther,2004,3(7):833-838.

共引文献35

同被引文献30

  • 1张晓菁,温泽清,张华玲,姚晓奕,李长忠.小干扰RNA抑制多药耐药基因表达并逆转耐药[J].中国实用妇科与产科杂志,2006,22(1):29-31. 被引量:3
  • 2仲建新,曹新平,王迪,张弘,丁润生,姜胜华,江枫,姚微,黄华,史锦云.醋酸甲羟孕酮增强顺铂对人卵巢癌耐药细胞抗癌作用的研究[J].现代妇产科进展,2007,16(8):594-598. 被引量:9
  • 3连利娟;林巧稚.妇科肿瘤学[M]北京:人民卫生出版社,2000410-424.
  • 4Iyer R R,Pluciennik A,Burdett V. DNA mismatch repair:functions and mechanisms[J].Chemical Reviews,2006,(02):302-323.
  • 5Yamane K,Schupp J E,Kinsella T J. BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine induced DNA mismatch damage[J].Cancer Research,2007,(13):6286-6292.
  • 6Woodhouse B C,Dianova I I,Parsons J L. Poly(ADP-ribose)polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks[J].Dna Repair,2008,(06):932-940.
  • 7Anderson G L,Mcintosh M,Wu L. Assessing lead time of selected ovarian cancerbiomarkers:a nested case-control study[J].Journal of the National Cancer Institute,2010,(01):26-38.doi:10.1093/jnci/djp438.
  • 8Mcintosh M W,Drescher C,Karlan B. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma[J].Gynecologic Oncology,2004,(01):9-15.
  • 9Rump A,Morikawa Y,Tanaka M. Binding of ovarian cancer antigen CA125/MUC16 tomesothelin mediates cell adhesion[J].Journal of Biological Chemistry,2004,(10):9190-9198.doi:10.1074/jbc.M312372200.
  • 10Cheng W F,Huang C Y,Chang M C. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma[J].British Journal of Cancer,2009,(07):1144-1153.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部